Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone

We present the case report of a patient with severe polycythaemia associated with tibolone. In our 65-year-old postmenopausal patient who initially presented with haemoglobin 203 g/L [115–160] and haematocrit 0.63 [0.32–0.47], the cessation of tibolone, a synthetic hormone replacement therapy, led t...

Descripción completa

Detalles Bibliográficos
Autores principales: Staples, Laura, Milder, Tamara, Choi, Philip Young-Ill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635276/
https://www.ncbi.nlm.nih.gov/pubmed/29090100
http://dx.doi.org/10.1155/2017/3476349
_version_ 1783270252371509248
author Staples, Laura
Milder, Tamara
Choi, Philip Young-Ill
author_facet Staples, Laura
Milder, Tamara
Choi, Philip Young-Ill
author_sort Staples, Laura
collection PubMed
description We present the case report of a patient with severe polycythaemia associated with tibolone. In our 65-year-old postmenopausal patient who initially presented with haemoglobin 203 g/L [115–160] and haematocrit 0.63 [0.32–0.47], the cessation of tibolone, a synthetic hormone replacement therapy, led to a dramatic and sustained resolution of this patient's polycythaemia to normal haematological values. Tibolone possesses oestrogenic, androgenic, and progestogenic properties. Tibolone therapy may be an infrequently recognized contributor towards polycythaemia in postmenopausal patients presenting to haematology clinics.
format Online
Article
Text
id pubmed-5635276
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56352762017-10-31 Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone Staples, Laura Milder, Tamara Choi, Philip Young-Ill Case Rep Hematol Case Report We present the case report of a patient with severe polycythaemia associated with tibolone. In our 65-year-old postmenopausal patient who initially presented with haemoglobin 203 g/L [115–160] and haematocrit 0.63 [0.32–0.47], the cessation of tibolone, a synthetic hormone replacement therapy, led to a dramatic and sustained resolution of this patient's polycythaemia to normal haematological values. Tibolone possesses oestrogenic, androgenic, and progestogenic properties. Tibolone therapy may be an infrequently recognized contributor towards polycythaemia in postmenopausal patients presenting to haematology clinics. Hindawi 2017 2017-09-27 /pmc/articles/PMC5635276/ /pubmed/29090100 http://dx.doi.org/10.1155/2017/3476349 Text en Copyright © 2017 Laura Staples et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Staples, Laura
Milder, Tamara
Choi, Philip Young-Ill
Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone
title Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone
title_full Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone
title_fullStr Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone
title_full_unstemmed Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone
title_short Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone
title_sort polycythaemia secondary to hormone replacement therapy with tibolone
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635276/
https://www.ncbi.nlm.nih.gov/pubmed/29090100
http://dx.doi.org/10.1155/2017/3476349
work_keys_str_mv AT stapleslaura polycythaemiasecondarytohormonereplacementtherapywithtibolone
AT mildertamara polycythaemiasecondarytohormonereplacementtherapywithtibolone
AT choiphilipyoungill polycythaemiasecondarytohormonereplacementtherapywithtibolone

Ejemplares similares